Sanofi and GSK Say COVID-19 Vaccine Did Well in Trial, Will Seek US Clearance

Sanofi logo at the company's headquarters in Paris, France, on Feb. 4, 2022. Benoit Tessier/Reuters

A COVID-19 vaccine created by Sanofi and GlaxoSmithKline (GSK) performed well in a clinical trial, the companies said on Feb. 23.

The vaccine was 100 percent effective against hospitalization, 75 percent effective against moderate to severe disease, and 58 percent effective against any symptoms, the companies said in a joint statement.